Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Regeneron Outperformance of S&P 500 by End of 2024  | Binary | 5 | 8 months ago | ||
First Human Trials of Regeneron-Mammoth CRISPR Therapy by 2025 | Binary | 5 | 8 months ago | ||
Regeneron Milestone Payment to Mammoth by End of 2024 | Binary | 5 | 8 months ago | ||
First Disease Targeted by Regeneron-Mammoth CRISPR Collaboration | Categorical | 5 | 8 months ago | ||
Greater Revenue Growth in 2024: Regeneron vs Mammoth Biosciences | Categorical | 5 | 8 months ago | ||
FDA Approval of Regeneron-Mammoth CRISPR Therapies by 2027 | Categorical | 5 | 8 months ago |